Skip to main content
https://pbs.twimg.com/media/FrmG6IcWYAQO9TW.jpg
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023 https://t.co/dWkakahHAi
Robert B Chao, MD
19-03-2023
×